Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $984,303.45 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 22,335 shares of Tempus AI stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $984,303.45. Following the completion of the transaction, the chief executive officer owned 2,230,721 shares in the company, valued at $98,307,874.47. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Trading Down 0.7%

Shares of NASDAQ:TEM opened at $46.18 on Friday. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The business’s fifty day simple moving average is $48.89 and its 200-day simple moving average is $59.29. The company has a market capitalization of $8.29 billion, a PE ratio of -26.85 and a beta of 3.99. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. During the same period last year, the business posted ($0.24) EPS. The business’s revenue was up 36.1% compared to the same quarter last year. As a group, equities research analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Silverback Asset Management LLC lifted its position in Tempus AI by 44.5% during the 1st quarter. Silverback Asset Management LLC now owns 35,700 shares of the company’s stock worth $1,614,000 after acquiring an additional 11,000 shares during the period. Vestor Capital LLC lifted its position in Tempus AI by 338.2% during the 1st quarter. Vestor Capital LLC now owns 1,538 shares of the company’s stock worth $70,000 after acquiring an additional 1,187 shares during the period. Arkadios Wealth Advisors lifted its position in Tempus AI by 9.6% during the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock worth $224,000 after acquiring an additional 435 shares during the period. Amundi lifted its position in Tempus AI by 30.4% during the 1st quarter. Amundi now owns 18,959 shares of the company’s stock worth $857,000 after acquiring an additional 4,417 shares during the period. Finally, California State Teachers Retirement System lifted its position in Tempus AI by 23.1% during the 1st quarter. California State Teachers Retirement System now owns 107,686 shares of the company’s stock worth $4,870,000 after acquiring an additional 20,182 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Analysts Set New Price Targets

Several research analysts recently weighed in on TEM shares. TD Cowen boosted their target price on Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. BTIG Research dropped their target price on Tempus AI from $90.00 to $80.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Robert W. Baird started coverage on Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 target price on the stock. Mizuho started coverage on Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price on the stock. Finally, Stifel Nicolaus set a $60.00 target price on Tempus AI in a research note on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.